Pioneers in cancer care

The Aktis Oncology team is pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumors.

Aktis Leadership Team

Matthew Roden, PhD

Matthew Roden, PhD

Matthew Roden, PhD

President, Chief Executive Officer

Paul L. Feldman, PhD

Paul L. Feldman, PhD

Paul L. Feldman, PhD

Chief Scientific Officer

Shulamit Ron-Bigger, PhD

Shulamit Ron-Bigger, PhD

Shulamit Ron-Bigger, PhD

Chief Operating Officer

Akos Czibere, MD, PhD

Chief Medical Officer

Tyler Benedum, PhD

Tyler Benedum, PhD

Tyler Benedum, PhD

Chief Technical Officer

R&D Leaders

Lorraine Horgan

Lorraine Horgan

Lorraine Horgan

Vice President,
Head of Program Management

Janet Horton, MD

Janet Horton, MD

Janet Horton, MD

Vice President,
Clinical Development

Jeff Kovacs, PhD

Jeff Kovacs, PhD

Jeff Kovacs, PhD

Vice President, Head of Biology

Daša Lipovšek, PhD

Daša Lipovšek, PhD

Daša Lipovšek, PhD

Vice President,
Head of Lead Discovery

Business Leaders

Karen McCarthy

Karen McCarthy

Karen McCarthy

Vice President,
Head of Finance

Kelly Polanco

Vice President,
Head of People & Culture

Carlos Rodriguez

Carlos Rodriguez

Carlos Rodriguez

Executive Director,
Corporate Development

Aktis Board of Directors

Todd Foley

Co-founder and Chairman

Helen Kim, MBA

Director

Oleg Nodelman

Director

Andrew Levin, MD, PhD

DIRECTOR

Lloyd M. Segal, MBA

INDEPENDENT DIRECTOR

Ken Herrmann, MD

Independent Director and Chair, Scientific Advisory Board

Matthew Roden, PhD

Director

James Carmichael, MD

OBSERVER

View Bio

Brian Goodman, PhD

Co-Founder, Observer

View Bio

Lauren Lee, PhD

OBSERVER

View Bio

Kevin Raidy

OBSERVER

View Bio

Markus Reschke, PhD

OBSERVER

View Bio

Jason Ruth

OBSERVER

View Bio

Adam Schayowitz

OBSERVER

View Bio

Vish Sridharan, MD

OBSERVER

View Bio

Aktis Scientific Advisors

Patrick Baeuerle, PhD

Co-founder & Advisor

Pankaj Bhargava, MD

Advisor

Ken Herrmann, MD

Independent Director and Chair, Scientific Advisory Board

Erik Chelius, PhD

Advisor

Johannes Czernin, MD

Advisor

Gary Glick, PhD

Advisor

Dane Wittrup, PhD

Advisor

Germo Gericke, MD

Advisor

Investors

RTW

Janus Henderson Investors

Our investor syndicate includes other undisclosed investors.

Join us

Join a team dedicated to discovering and developing transformative therapies that put solid cancers into remission.

View Careers

Scientist in lab coat working at computer desk